MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ
1.830
-0.020
-1.08%
Opening 12:04 03/28 EDT
OPEN
1.810
PREV CLOSE
1.850
HIGH
1.845
LOW
1.810
VOLUME
6.22K
TURNOVER
0
52 WEEK HIGH
5.10
52 WEEK LOW
0.9694
MARKET CAP
7.83M
P/E (TTM)
-0.4317
1D
5D
1M
3M
1Y
5Y
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at PSTV last week (0318-0322)?
Weekly Report · 3d ago
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Plus Therapeutics (PSTV) was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target for the company. The company's lead asset, rhenium obisbemeda, has shown promising results in clinical trials.
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals (MIST) and Plus Therapeutics (PSTV) have been upgraded to Buy by 2 analysts today. The company's shares closed at $1.65 on Friday. The analysts are bullish on the Healthcare sector and the company's prospects. Plus TherAPEutics and Milestone PharmaceuticalS have a combined market value of $1 billion.
TipRanks · 6d ago
Weekly Report: what happened at PSTV last week (0311-0315)?
Weekly Report · 03/18 09:53
Plus Therapeutics CEO’s Insightful Presentation Now Available
TipRanks · 03/13 12:12
Weekly Report: what happened at PSTV last week (0304-0308)?
Weekly Report · 03/11 09:52
Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials
TipRanks · 03/07 15:35
More
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

Webull offers Plus Therapeutics Inc (USA) stock information, including NASDAQ: PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.